Table 1. Characteristics of previous LD.
| Age at LD diagnosis – years (median, IQR) | 60 (48–67) |
|---|---|
| Center – n (%) | |
| Toulouse | 35 (44) |
| Marseille | 45 (56) |
| LD type – n (%) Aggressive NHL | 22 (28) |
| DLBCL | 13 (16) |
| MCL | 5 (6) |
| BL | 2 (3) |
| Other | 2 (3) |
| Indolent NHL | 32 (40) |
| FL | 14 (18) |
| Chronic lymphocytic leukemia | 8 (10) |
| MALT/SALT | 4 (5) |
| Lymphocytic | 1 (1) |
| Unknown | 1 (1) |
| Hodgkin lymphoma | 11 (14) |
| T-cell lymphoma | 5 (6) |
| Not known | 2 (3) |
| Stage at diagnosis – n (%) | |
| Localized* | 14 (18) |
| Advanced** | 46 (58) |
| Binet A | 1 (1) |
| Binet B-C | 5 (6) |
| Unknown | 14 (18) |
| Treatment – n (%) | 80 (100) |
| Chemotherapy only | 21 (26) |
| Radiotherapy only | 1 (1) |
| Chemotherapy + radiotherapy | 19 (24) |
| R-chemotherapy | 28 (33) |
| R-chemotherapy + radiotherapy | 6 (8) |
| Unknown | 5 (6) |
| Chemotherapy agent*** | |
| Alkylating agents | 66/68 (97) |
| Fludarabine-based | 11/68 (16) |
| CHOP-like | 34/68 (50) |
| Chlorambucil | 19/68 (28) |
| Rituximab | 34/70 (49) |
| No. of treatment lines (median, min-max) | 1 (1–6) |
| 2 lines - n (%) | 30 (38) |
| ≥ 3 lines – n (%) | 9 (11) |
| Autologous stem cell transplantation – n (%) | 16 (20) |
Abbreviations: LD: lymphoid disease; NHL: non-Hodgkin Lymphoma; DLBCL: diffuse large B cell lymphoma; MCL: mantle cell lymphoma; BL: Burkitt-like; FL: follicular lymphoma; NOS: not otherwise specified.
*Localized is defined by Ann-Arbor classification 1–2; ** Advanced is defined by Ann-Arbor stage III-IV; ***At first line or later.